BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/10/2015 10:35:00 AM | Browse: 632 | Download: 721
Publication Name World Journal of Gastroenterology
Manuscript ID 14030
Country/Territory Germany
2014-09-15 13:51
Peer-Review Started
2014-09-15 20:44
To Make the First Decision
2014-10-14 16:55
Return for Revision
2014-10-17 08:23
2014-10-24 21:31
Second Decision
2014-11-18 10:56
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-12-01 13:43
Articles in Press
2014-12-01 14:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-03-07 17:00
Publish the Manuscript Online
2015-03-19 16:57
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Retrospective Study
Article Title Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis
Manuscript Source Unsolicited Manuscript
All Author List Enayatullah Baki, Philipp Zwickel, Anna Zawierucha, Robert Ehehalt, Daniel Gotthardt, Wolfgang Stremmel and Annika Gauss
Funding Agency and Grant Number
Corresponding author Annika Gauss, MD, Division of Gastroenterology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. annika.gauss@med.uni-heidelberg.de
Key Words Inflammatory bowel disease; Tumor necrosis factor α inhibitors; Ulcerative colitis; Outcome; Real life
Core Tip Tumor necrosis factor alpha inhibitors are a widely accepted therapeutic option for the treatment of ulcerative colitis. Results from different real-life settings on their use in ulcerative colitis are controversial. Weighing anti tumor necrosis factor alpha against other treatment options, it is very important to decide on the best therapy for a patient. This retrospective study from a tertiary referral centre shows a rate of steroid-free clinical remission of 22.2% and a colectomy rate of 20.8% for ambulatory patients with ulcerative colitis under therapy with tumor necrosis factor alpha inhibitors. These rather disappointing outcomes should be thoroughly discussed with the patients before start of therapy.
Publish Date 2015-03-19 16:57
Citation Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol 2015; 21(11): 3282-3290
Url http://www.wjgnet.com/1007-9327/full/v21/i11/3282.htm
DOI http://dx.doi.org/10.3748/wjg.v21.i11.3282
Full Article (PDF) WJG-21-3282.pdf
Full Article (Word) WJG-21-3282.doc
Manuscript File 14030-Review.DOC
Answering Reviewers 14030-Answering reviewers.pdf
Biostatistics Review Certificate Biostatistician_Review_Report_20140914224522.pdf
Copyright License Agreement 14030-Copyright assignment.pdf
Institutional Review Board Approval Form or Document Ethics_Committee_20140914224436.pdf
Non-Native Speakers of English Editing Certificate 14030-Language certificate.pdf
Peer-review Report 14030-Peer review(s).pdf
Scientific Misconduct Check 14030-CorssCheck.jpg
Scientific Editor Work List 14030-Scientific editor work list.pdf